Analyzing Windtree Therapeutics (WINT) & SIGA Technologies (SIGA)
Windtree Therapeutics (OTCMKTS: WINT) and SIGA Technologies (OTCMKTS:SIGA) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, institutional ownership, analyst recommendations, profitability, dividends, risk and earnings.
This is a breakdown of current ratings and price targets for Windtree Therapeutics and SIGA Technologies, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Volatility and Risk
Windtree Therapeutics has a beta of 1.75, indicating that its share price is 75% more volatile than the S&P 500. Comparatively, SIGA Technologies has a beta of 0.73, indicating that its share price is 27% less volatile than the S&P 500.
Earnings & Valuation
This table compares Windtree Therapeutics and SIGA Technologies’ revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Windtree Therapeutics||$2.04 million||25.16||-$39.49 million||($71.83)||-0.01|
|SIGA Technologies||$14.99 million||25.53||-$39.69 million||($0.53)||-9.15|
Windtree Therapeutics has higher earnings, but lower revenue than SIGA Technologies. SIGA Technologies is trading at a lower price-to-earnings ratio than Windtree Therapeutics, indicating that it is currently the more affordable of the two stocks.
Insider and Institutional Ownership
0.3% of Windtree Therapeutics shares are held by institutional investors. Comparatively, 6.7% of SIGA Technologies shares are held by institutional investors. 0.8% of Windtree Therapeutics shares are held by insiders. Comparatively, 4.7% of SIGA Technologies shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
This table compares Windtree Therapeutics and SIGA Technologies’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
SIGA Technologies beats Windtree Therapeutics on 7 of the 10 factors compared between the two stocks.
About Windtree Therapeutics
Windtree Therapeutics, Inc., formerly Discovery Laboratories, Inc., is a biotechnology company. The Company is focused on developing KL4 surfactant therapies for respiratory diseases and other potential applications. The Company operates through the research and development of products focused on surfactant therapies for respiratory disorders and diseases, and the manufacture and commercial sales of approved products segment. The Company’s technology platform includes a synthetic, peptide-containing surfactant (KL4 surfactant) that is structurally similar to endogenous pulmonary surfactant, and drug delivery technologies being developed to enable non-invasive administration of aerosolized KL4 surfactant. The Company’s core development program, AEROSURF (lucinactant for inhalation), is focused on improving the management of respiratory distress syndrome (RDS) in premature infants, a respiratory condition that can result in long-term respiratory problems, developmental delay and death.
About SIGA Technologies
SIGA Technologies, Inc. is engaged in the development and commercialization of solutions for various unmet medical needs and biothreats. The Company’s lead product is TPOXX, an orally administered antiviral drug that targets orthopoxviruses infections. TPOXX is a small-molecule drug delivered to the Strategic Stockpile under the Project BioShield Act of 2004 (Project BioShield). TPOXX is an investigational product that is not approved by the United States Food and Drug Administration (FDA) as a treatment of smallpox or any other indication. The Company relies on and uses third parties known as contract manufacturing organizations (CMOs) to procure commercial raw materials and supplies, and to manufacture TPOXX. The Company identified a lead pre-clinical drug candidate with activity against four serotypes of the virus and which has shown efficacy in a murine model of disease.
Receive News & Ratings for Windtree Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Windtree Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.